Unbiased Analysis of Today's Healthcare Issues

Archive for the 'Public Health' Category

Can physicians affect medication adherence?

According to a recent study by Koulayev, Simeonova, and Skipper (2016) using data from Denmark, the answer is ‘yes’. Non-compliance with medication therapy remains an unsolved and expensive problem for healthcare systems around the world, yet we know little about the factors that affect a patient’s decision to follow treatment recommendations. In particular, there is […]

Read the rest of this entry »

Sounds like a good idea?

Kaiser’s family of website has some interesting posts of late.  The Kaiser Family Foundation presents 10 Essential Facts about Medicare Prescription Drug Spending.  They show the increasing price of U.S. prescription drugs spending over time. They also show that many patients with Medicare Part D, still bear a large share of prescription drug costs for […]

Read the rest of this entry »

Children and Cost-Benefit Analysis

Alan Balch, PhD, discusses the Institute for Clinical and Economic Review’s (ICER’s) Value Assessment Framework tool that aims to provide stakeholders in healthcare with evidence to make more informed decisions regarding new cancer therapies. Dr Balch also considers limitations to the tool’s effectiveness. Plus, he even discusses why if we lived life using a strict […]

Read the rest of this entry »

Gates: US Drug pricing system is ‘Better Than Most’

There has been a lot of criticism of drug prices in the U.S. One person not included the chorus of critics is Bill Gates. In an interview with Bloomberg, he said: “The current system is better than most other systems one can imagine,” Gates said in an interview on Bloomberg Television. “The drug companies are […]

Read the rest of this entry »

Brexit = upheaval for drug makers

Will the European Medicines Agency (EMA) need to re-located after Brexit? According to a Reuters story, the answer is yes. The EMA is a London-based organization that approves treatments for all EU countries. As the UK leaves the EU, however, EMA is expected to have to relocate. 600 individuals work for EMA. More important is […]

Read the rest of this entry »

Patient perspective on cancer care funding

Improvement in survival (a.k.a. efficiacy) clearly are important, but what other factors matter?  According to a systematic literature review by MacLeod, Harris and Mahal (2016), these factors include: patients favour funding for cancer medicines that improve health outcomes demonstrated by ‘clinical efficacy’ [Oh et al.], ‘prolonged survival’ [Goldman et al., Seabury et al. Lakdawalla et al.] and/or […]

Read the rest of this entry »

Infectious Disease: Themes

An interesting post by Nicolas Bagley at the Incidental Economist provides a brief overview of a class he taught on infectious diseases and the law.  Looking at diseases ranging from cholera, Spanish flu, polio, AIDS, SARS, and Ebola, Bagley claims that ten key themes emerged: Governments are typically unprepared, disorganized, and resistant to taking steps […]

Read the rest of this entry »

Avoiding Lead poisoning

Lead poisoning, perhaps surprisingly, is still a major problem in the U.S. Lead poisoning in the water supply in Flint, Michigan is grabbing all the headlines, but other sources of lead poisoning are also problematic. John Oliver has even dedicated an entire show to the problem of lead poisoning in the U.S. How do you […]

Read the rest of this entry »

What is the FDA doing about opioids?

The FDA is planning to put additional scrutiny on the use and approval of opioids in order to prevent opioid abuse and addiction.  Here is their plan: Re-examine the risk-benefit paradigm for opioids and ensure that the agency considers their wider public health effects Convene an expert advisory committee before approving any new drug application for an […]

Read the rest of this entry »

Innovation vs. Equity in Health Care Philanthropy

In the Denver Post, Dottie Lamm makes discusses Larry Ellison’s hope to live forever and his donation towards anti-aging research.  Ellison has donated $450 million to anti-aging research. Ms. Lamm worries that this research will only benefit the rich. If such measures are available only to billionaires, or millionaires, or even to “one-percenters,” I see […]

Read the rest of this entry »